Innate Pharma (IPH) Stifel 2026 Healthcare Conference 2026 summary

Portfolio and near-term milestones

• Focused on differentiated antibody-drug conjugates; lead asset IPH4502 targets Nectin-4 in solid tumors, with dose-finding data scheduled for presentation the week of Nov. 18, 2026.

• Lacutamab targets KIR3DL2 in cutaneous T-cell lymphoma (CTCL); Sobi is responsible for commercialization after accelerated approval.

• Monalizumab, an NKG2A-targeted antibody partnered with AstraZeneca, is being tested in stage III unresectable non-small cell lung cancer; PACIFIC-9 Phase III readout expected in H1 2027.

Lacutamab: clinical evidence and positioning

• In post-mogamulizumab Sézary syndrome, TELLOMAK Phase II showed 43% ORR, 8.3-month PFS and clinical benefit rate near 90%; data supported FDA Breakthrough Therapy designation.

• In mycosis fungoides (MF), Phase II showed 19% ORR, disease control near 90% and PFS around 10 months; quality of life improved rapidly in both CTCL subgroups.

• KIR3DL2 expression on malignant T cells is the basis for selective targeting; patients in Phase I have received treatment for over seven years and Phase II patients for over five years.

• MF five-year survival falls from 78% at stage IIA to 47% at stage IIB; the strategy aims to establish lacutamab as an early systemic option, including for stage IB or IIA patients.

• In Sézary syndrome, physicians may use lacutamab after mogamulizumab or potentially earlier; anticipated NCCN guideline inclusion could support use across treatment stages.

Lacutamab: development and commercialization

• TELLOMAK-3 has randomized, statistically powered cohorts: post-mogamulizumab Sézary syndrome, lacutamab vs romidepsin; MF, lacutamab vs mogamulizumab. Both use PFS by blinded independent review as primary endpoint.

• Key secondary endpoints are overall survival in Sézary syndrome and health-related quality of life in MF; the MF cohort is designed to test superiority over mogamulizumab.

• A €75 million upfront payment and €14 million in potential short-term milestones supported TELLOMAK-3; the development team plans to run the confirmatory trial and submit the accelerated-approval BLA.

• First TELLOMAK-3 patient initiation is expected in Q1 2027; BLA submission is planned for H2 2027 and accelerated approval for H1 2028, with Sobi preparing for commercialization.

• MF recruitment is expected to take 15–18 months, followed by ~12 months of follow-up; data are targeted for 2029, with MF full approval targeted for 2030 and Sézary syndrome later.